Company / Current Liabilities per Share
Fulcrum Therapeutics, Inc. Current Liabilities per Share History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities per Share
$205.95
FY2025
5-year range
$178.18 / $542.94
FY2021-FY2025
Trend
+15.6%
vs FY2024
Sector context
#3 of 210
Health Care
What the data says
Among 210 Health Care companies, Fulcrum Therapeutics, Inc. is in the bottom 1% for current liabilities per share. Current Liabilities per Share returned to growth in FY2025 after 6 years of decline, reaching $205.95.
Based on SEC 10-K filings.
205.95 in FY2025 with a 5-year CAGR of -27.9%. Ranks 3rd among 210 companies in Health Care.
Improved from $223.05 to $205.95 over the past 2 years.
Health Care sector context is included.
Current Liabilities per Share over time
Growth rates
- 3-Year CAGR
- -17.9%
- 5-Year CAGR
- -27.9%
- 10-Year CAGR
- -
Sector benchmark
+765.8% above sector average
Key checks
Key Insights
- In FY2025, current liabilities per share increased 15.6% year-over-year.
- Ranks #3 out of 210 companies in the Health Care sector.
- Peak current liabilities per share was recorded in FY2018.
- Lowest current liabilities per share in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 8.44 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current Liabilities per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $205.95 | +15.6% |
| FY2024 | $178.18 | -20.1% |
| FY2023 | $223.05 | -40.0% |
| FY2022 | $371.74 | -31.5% |
| FY2021 | $542.94 | -48.5% |
| FY2020 | $1054.07 | -4.1% |
| FY2019 | $1099.04 | -67.3% |
| FY2018 | $3364.36 | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026